A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Noelia Nebot et al.|Annals of Oncology|2016Cited by 145
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Udai Banerji, Ruth Plummer et al.|British Journal of Cancer|2023Cited by 36
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.Elizabeth Ruth Plummer, Udai Banerji, Rebecca Kristeleit et al.|Journal of Clinical Oncology|2019Cited by 31
610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent MesotheliomaJean‐Charles Soria, M.J. Millward, Ruth Plummer et al.|European Journal of Cancer|2012Cited by 8
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.T.R. Jeffry Evans, Jordan Berlin, Sarah P. Blagden et al.|Journal of Clinical Oncology|2019Cited by 7